POTENSI INTERAKSI OBAT PADA PASIEN HIPERTENSI DENGAN PENYAKIT PENYERTA DI RSUD PREMBUN
POTENTIAL DRUG INTERACTIONS IN HYPERTENSION PATIENTS WITH COMORBID DISEASES AT PREMBUN HOSPITAL
DOI:
https://doi.org/10.37090/jfl.v13i2.1762Abstract
In the treatment of hypertension accompanied by comorbidities, there are many occurrences, so the potential for polypharmacy is very large, which causes the possibility of drug interactions. Drug interactions cause various problems such as decreased therapeutic effects, increased toxicity, or altered pharmacological effects of a drug.This study aims to describe the potential interaction of hypertension drugs in inpatients at Prembun Hospital for the 2023 period. This research is descriptive research by collecting data retrospectively. Data on the use of antihypertensive drugs and data on inpatient visits were obtained from the Inpatient Institution of Prembun Hospital for the 2023 Period. Out of a total of 100 patients, there were 93 interactions (93%). There were 3 interactions, namely the most severe level, namely moderate interactions as many as 150 interactions (58.3%) occurred in drugs between Aspirin and Amlodipine, the severity of minor interactions as many as 71 interactions (27.6%) occurred between Amlodipine drugs and Furosemide, and the least severe level of drug interactions was major interactions as many as 36 interactions (14%) occurred between Spironolactone and Candesartan. From the results of the study, it can be concluded that there is 93% interaction in the use of hypertension drugs, and 7% there is no interaction in the use of hypertension drugs.
Keywords: Hypertension, Comorbidities, Interaction
References
[1] Kemenkes RI, “Pedoman Pelayanan Kefarmasian pada Hipertensi. Diakses Pada 15 Februari 2022,” Kementeri. Kesehat. RI, pp. 5–24, 2019.
[2] Kementerian Kesehatan RI, “Riskendas 2018,” Lap. Nas. Riskesndas 2018, vol. 44, no. 8, pp. 181–222, 2018, [Online]. Available: http://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf
[3] I. B. M. Reyaan, C. Kuning, and I. K. Adnyana, “Studi Potensi Interaksi Obat pada Resep Polifarmasi di Dua Apotek Kota Bandung,” (Journal Manag. Pharm. Pract., vol. 11, no. 3, p. 145, 2021, doi: 10.22146/jmpf.56931.
[4] O. A. Agustin and Fitrianingsih, “Kajian Interaksi Obat Berdasarkan Kategori Signifikansi Klinis Terhadap Pola Peresepan Pasien Rawat Jalan Di Apotek X Jambi,” e-SEHAD, vol. 1, no. 1, pp. 1–10, 2020.
[5] M. Rahmadhani, “Faktor-Faktor Yang Mempengaruhi Terjadinya Hipertensi Pada Masyarakat Di Kampung Bedagai Kota Pinang,” J. Kedokt. STM (Sains dan Teknol. Med., vol. 4, no. 1, pp. 52–62, 2021, doi: 10.30743/stm.v4i1.132.
[6] V. N. Amalia and U. Sjarqiah, “Gambaran Karakteristik Hipertensi Pada Pasien Lansia di Rumah Sakit Islam Jakarta Sukapura Tahun 2020,” Muhammadiyah J. Geriatr., vol. 3, no. 2, p. 62, 2023, doi: 10.24853/mujg.3.2.62-68.
[7] V. Shetty, M. N. Chowta, N. Chowta K, A. Shenoy, A. Kamath, and P. Kamath, “Evaluation of Potential Drug-Drug Interactions with Medications Prescribed to Geriatric Patients in a Tertiary Care Hospital,” J. Aging Res., vol. 2018, 2018, doi: 10.1155/2018/5728957.
[8] U. Khairiyah, M. A. Yuswar, and N. U. Purwanti, “Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi di Instalasi Rawat Jalan Rumah Sakit,” J. Syifa Sci. Clin. Reasearch, vol. 4, pp. 609–617, 2022.
[9] A. Febri Nilansari, N. Munif Yasin, and D. A. Puspandari, “Gambaran Pola Penggunaan Obat Antihipertensi Pada Pasien Rawat Inap di RSUD Panembahan Senopati,” Lumbung Farm. J. Ilmu Kefarmasian, vol. 1, no. 2, p. 73, 2020, doi: 10.31764/lf.v1i2.2577.
[10] I. L. Fitria, “Profil Penggunaan Antihipertensi Pasien Rawat Jalan Dengan Atau Tanpa Komorbiditas Di Rumah Sakit Era Medika Periode Januari-Maret 2018,” no. 1, pp. 430–439, 2018.
[11] Isrof Hadidi, “Profil Penggunaan Obat Pada Pasien Hipertensi Dengan Penyakit Penyerta Rawat Inap Di Rumah Sakit Dr Asmir DKT Salatiga Periode Januari-Juli 2019,” vol. 21, no. 1, pp. 1–9, 2020.
[12] I. T. Pasangka, H. Tjitrosantoso, and A. Lolo, “Identifikasi Potensi Interaksi Obat Pada Pasien Gagal Ginjal Rawat Inap Di RSUP Prof. Dr. R. D. Kandou Manado,” Ilm. Farm., vol. 6, no. 4, pp. 119–129, 2017.
[13] K. T. M. Sleem A., Masood I., “Clinical relevancy and determinants of potential drug – drug interactions in chronic kidney disease patients : results from a retrospective analysis,” pp. 71–77, 2017.
[14] C. E. Puspitasari, R. Widiyastuti, N. M. A. R. Dewi, O. Q. L. Woro, and A. Syamsun, “Profil Drug Related Problems (DRPs) pada Pasien Hipertensi di Instalasi Rawat Jalan Rumah Sakit Pemerintah di Kota Mataram Tahun 2018,” J. Sains dan Kesehat., vol. 4, no. SE-1, pp. 77–87, 2022, doi: 10.25026/jsk.v4ise-1.1692.
[15] F. Effendi and H. B. Harimu, “Gambaran Potensi Interaksi Obat Antihipertensi Oral (Golongan Ace Inhibitor Dan Angiotensin Receptor Blocker) Pada Pasien Poli Jantung Rsud Ciawi Bogor,” J. Kesehat. Mahardika, vol. 8, no. 2, pp. 1–9, 2022, doi: 10.54867/jkm.v8i2.59.
[16] G. R. Bailie, C. A. Johnson, N. A. Mason, and W. L. St. Peter, “MED Facts Pocket guide of drug interactions Second Edition, Philadelpia,” 2021.
[17] Salfitri, Nurmainah, and M. Akib Yuswar, “Study Of Antihypertensive Drug Interactions In Hemodialysis Patients At Yarsi Hospital Pontianak In 2017,” J. Mhs. Farm. Fak. Kedokt. UNTAN, vol. 1, no. 1, 2017.
[18] I. Kancirová, M. Jašová, I. Waczulíková, T. Ravingerová, A. Ziegelhöffer, and M. Ferko, “Effect of antihypertensive agents - Captopril and nifedipine - On the functional properties of rat heart mitochondria,” Iran. J. Basic Med. Sci., vol. 19, no. 6, pp. 615–623, 2016.
[19] PERHI, “Konsensus Penatalaksanaan Hipertensi 2019,” Indones. Soc. Hipertens. Indones., pp. 1–90, 2019.
[20] Y. Handelsman et al., “American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary.,” Endocr. Pract., vol. 17, no. 2, pp. 287–302, 2011, doi: 10.4158/EP.17.2.287.
[21] P. Permaiswari, “Kajian Interaksi Obat Terhadap Pasien Geriatri Dengan Penyakit Hipertensi di Rumah Sakit Pelabuhan Jakarta Utara,” Skripsi, 2018.
[22] P. M. A. Eliani Tirta, P. P. Empuadji, and P. Y. B. Setiawan, “Kajian Retrospektif Potensi Interaksi Obat Hipertensi Pada Peresepan Pasien Poli Penyakit Dalam Di Rumah Sakit Swasta X Di Denpasar,” J. Ris. Kesehat. Nas., vol. 7, no. 2, pp. 98–103, 2023, doi: 10.37294/jrkn.v7i2.501.
[23] S. Palanisamy, K. S. A. Kumaran, and A. Rajasekaran, “A study on assessment, monitoring and reporting of adverse drug reactions in Indian hospital,” Asian J. Pharm. Clin. Res., vol. 4, no. 3, pp. 112–116, 2019.
[24] J. Ansari, “Drug interaction and pharmacist,” J. Young Pharm., vol. 2, no. 3, pp. 326–331, 2020, doi: 10.4103/0975-1483.66807.
